Sirolimus in pediatric renal transplantation

Pediatric Transplantation

Volumn 15, Issue 7, 2011, Pages 673-685

  Kasap, Belde ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

pediatric renal transplantation; sirolimus

Indexed keywords

CALCINEURIN INHIBITOR; ERYTHROPOIETIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CHRONIC GRAFT REJECTION; DIABETES MELLITUS; DIARRHEA; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; EDEMA; ERECTILE DYSFUNCTION; GRAFT DYSFUNCTION; GRAFT SURVIVAL; GROWTH DISORDER; HEALTH CARE QUALITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER FUNCTION; LYMPHEDEMA; LYMPHOCELE; MOUTH ULCER; MYCOSIS; NEPHRITIS; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PAIN; PNEUMONIA; PROTEINURIA; PSEUDOCYST; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VIRUS INFECTION; WOUND HEALING;

CHILD; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; PEDIATRICS; PNEUMONIA; PROTEINURIA; SIROLIMUS; THROMBOCYTOPENIA; TIME FACTORS; TOR SERINE-THREONINE KINASES; WOUND HEALING;

EID: 80054982166     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2011.01575.x     Document Type: Article

References (121)

1. Gupta P, Kaufman S, Fishbein TM,. Sirolimus for solid organ transplantation in children. Pediatr Transplant 2005: 9: 269-276.
2. Sehgal SN,. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc 2003: 35 (3 Suppl.): 7S-14S.
3. Hymes LC, Warshaw BL,. Sirolimus in pediatric patients: Results in the first 6 months post-renal transplant. Pediatr Transplant 2005: 9: 520-522.
4. Garcia CD, Bittencourt VB, Alves AB, et al., Conversion to sirolimus in pediatric renal transplantation recipients. Transplant Proc 2006: 38: 1901-1903.
5. Ettenger RB, Grimm EM,. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients. Am J Kidney Dis 2001: 38 (4 Suppl. 2): S22-S28.
6. Vilalta R, Vila A, Nieto J, Callis L,. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. Transplant Proc 2003: 35: 703-704.
7. Augustine JJ, Bodziak KA, Hricik DE,. Use of sirolimus in solid organ transplantation. Drugs 2007: 67: 369-391.
8. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR,. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992: 358: 70-73.
9. Thomson AW, Turnquist HR, Raimondi G,. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 2009: 9: 324-337.
10. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB,. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007: 7: 1722-1732.
11. Ferrer IR, Araki K, Ford ML,. Paradoxical aspects of rapamycin immunobiology in transplantation. Am J Transplant 2011: 11: 654-659.
12. Liu KL, Chu SH, Chiang YJ, Wu CT, Chen Y,. Sirolimus (rapamycin) reduces the incidence of acute rejection episodes in renal transplantation: An initial experience in Taiwan. Transplant Proc 2004: 36: 2051-2052.
13. Abraham RT, Wiederrecht GJ,. Immunopharmacology of rapamycin. Annu Rev Immunol 1996: 14: 483-510.
14. Tejani A, Alexander S, Ettenger R, et al., Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant 2004: 8: 151-160.
15. Zimmerman JJ, Kahan BD,. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997: 37: 405-415.
16. Schachter AD, Meyers KE, Spanes LD, et al., Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004: 8: 171-177.
17. Venkataramanan R, Sindhi R,. Sirolimus pharmacokinetic differences between children and adults. Pediatr Transplant 2006: 10: 872-874.
18. Schubert M, Venkataramanan R, Holt DW, et al., Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004: 4: 767-773.
19. Forbes N, Schachter AD, Yasin A, Sharma AP, Filler G,. Limited sampling strategies for sirolimus after pediatric renal transplantation. Pediatr Transplant 2009: 13: 1020-1026.
20. Schachter AD, Benfield MR, Wyatt RJ, et al., Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. Pediatr Transplant 2006: 10: 914-919.
21. Zochowska D, Bartłomiejczyk I, Kamińska A, Senatorski G, Paczek L,. High-performance liquid chromatography versus immunoassay for the measurement of sirolimus: Comparison of two methods. Transplant Proc 2006: 38: 78-80.
22. Falger JC, Mueller T, Arbeiter K, et al., Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Pediatr Transplant 2006: 10: 474-478.
23. El-Sabrout R, Delaney V, Qadir M, Butt F, Hanson P, Butt KM,. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients - a single center experience. Transplant Proc 2003: 35 (3 Suppl.): 89S-94S.
24. Sindhi R,. Sirolimus in pediatric transplant recipients. Transplant Proc 2003: 35: 113S-114S.
25. McDonald RA, Smith JM, Ho M, et al., Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008: 8: 984-989.
26. Ibáñez JP, Monteverde ML, Goldberg J, Diaz MA, Turconi A,. Sirolimus in pediatric renal transplantation. Transplant Proc 2005: 37: 682-684.
27. Macdonald AS,. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 2003: 35: 201S-208S.
28. Filler G, Womiloju T, Feber J, Lepage N, Christians U,. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 2005: 5: 2005-2010.
29. Zimmerman JJ, Harper D, Getsy J, Jusko WJ,. Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol 2003: 43: 1168-1176.
30. Grimm EM, Kelly PA, Swinford RD, Gitomer JJ, Kahan BD,. Sirolimus pharmacokinetics in pediatric renal transplants. Pediatr Transplant 2000: 4 (Suppl. 2): S86A (Abstr).
31. Vu MD, Qi S, Xu D, et al., Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997: 64: 1853-1856.
32. Vu MD, Qi S, Xu D, et al., Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998: 66: 1575-1580.
33. Harmon W, Meyers K, Ingelfinger J, et al., Safety and efficacy of a calcineurin inhibitor avoidance regimen in pediatric renal transplantation. J Am Soc Nephrol 2006: 17: 1735-1745.
34. Iorember FM, Patel HP, Ohana A, et al., Steroid avoidance using sirolimus and cyclosporine in pediatric renal transplantation: One year analysis. Pediatr Transplant 2010: 14: 93-99.
35. Ibáñez JP, Monteverde ML, Diaz MA, Goldberg J, Turconi AF,. Sirolimus in chronic allograft nephropathy in pediatric recipients. Pediatr Transplant 2007: 11: 777-780.
36. Powell HR, Kara T, Jones CL,. Early experience with conversion to sirolimus in a pediatric renal transplant population. Pediatr Nephrol 2007: 22: 1773-1777.
37. Hymes LC, Warshaw BL, Amaral SG, Greenbaum LA,. Tacrolimus withdrawal and conversion to sirolimus at three months post-pediatric renal transplantation. Pediatr Transplant 2008: 12: 773-777.
38. Hymes LC, Warshaw BL,. Five-year experience using sirolimus-based, calcineurin inhibitor-free immunosuppression in pediatric renal transplantation. Pediatr Transplant 2011: 15: 437-441.
39. Benfield MR, Bartosh S, Ikle D, et al., A randomized double-blind, placebo controlled trial of steroid withdrawal after pediatric renal transplantation. Am J Transplant 2010: 10: 81-88.
40. Höcker B, Feneberg R, Köpf S, et al., SRL-based immunosuppression vs. CNI minimization in pediatric renal transplant recipients with chronic CNI nephrotoxicity. Pediatr Transplant 2006: 10: 593-601.
41. Weintraub L, Li L, Kambham N, et al., Patient selection critical for calcineurin inhibitor withdrawal in pediatric kidney transplantation. Pediatr Transplant 2008: 12: 541-549.
42. Saber LT, Ikeda MY, Almeida JM,. Posttransplantation conversion to sirolimus-based immunosuppression: A single center experience. Transplant Proc 2007: 39: 3098-3100.
43. Bumbea V, Kamar N, Ribes D, et al., Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005: 20: 2517-2523.
44. Chueh SC, Kahan BD,. Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: Incidence, risk factors, progression, and prognosis. Transplantation 2003: 76: 375-382.
45. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al., Effect of sirolimus on the metabolism of apoBl00-containing lipoproteins in renal transplant patients. Transplantation 2001: 72: 1244-1250.
46. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al., Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002: 43: 1170-1180.
47. Evans M, Rees A,. Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf 2002: 25: 649-663.
48. Marti HP, Frey FJ,. Nephrotoxicity of rapamycin: An emerging problem in clinical medicine. Nephrol Dial Transplant 2005: 20: 13-15.
49. Fervenza FC, Fitzpatrick PM, Mertz J, et al., Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004: 19: 1288-1292.
50. Kahan BD,. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003: 35: 37S-51S.
51. Sartelet H, Toupance O, Lorenzato M, et al., Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant 2005: 5: 2441-2447.
52. Crew RJ, Radhakrishnan J, Cohen DJ, et al., De novo thrombotic microangiopathy following treatment with sirolimus: Report of two cases. Nephrol Dial Transplant 2005: 20: 203-209.
53. Smith KD, Wrenshall LE, Nicosia RF, et al., Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003: 14: 1037-1045.
54. Straathof-Galema L, Wetzels JF, Dijkman HB, Steenbergen EJ, Hilbrands LB,. Sirolimus-associated heavy proteinuria in a renal transplant recipient: Evidence for a tubular mechanism. Am J Transplant 2006: 6: 429-433.
55. Lieberthal W, Fuhro R, Andry CC, et al., Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001: 281: F693-F706.
56. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF,. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 2004: 65: 1262-1271.
57. Andoh TF, Burdmann EA, Fransechini N, Houghton DC, Bennett WM,. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996: 50: 1110-1117.
58. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C,. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005: 80: 1198-1203.
59. Sahin GM, Sahin S, Kantarci G, Ergin H,. Proteinuria after conversion to sirolimus in renal transplant recipients. Transplant Proc 2006: 38: 3473-3475.
60. Franco AF, Martini D, Abensur H, Noronha IL,. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007: 39: 449-452.
61. Pinheiro HS, Amaro TA, Braga AM, Bastos MG,. Post-rapamycin proteinuria: Incidence, evolution, and therapeutic handling at a single center. Transplant Proc 2006: 38: 3476-3478.
62. Butani L,. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004: 78: 1362-1366.
63. Saurina A, Campistol JM, Lario S, Oppenheimer F, Diekmann F,. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration. Transplant Proc 2007: 39: 2138-2141.
64. Valente JF, Hricik D, Weigel K, et al., Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003: 3: 1128-1134.
65. Dean PG, Lund WJ, Larson TS, et al., Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004: 77: 1555-1561.
66. Mahé E, Morelon E, Lechaton S, et al., Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005: 79: 476-482.
67. Van Gelder T, Ter Meulen CG, Hené R, Weimar W, Hoitsma A,. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003: 5: 788-791.
68. Mahé E, Morelon E, Lechaton S, Kreis H, De Prost Y, Bodemer C,. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007: 214: 205-209.
69. Lykavieris P, Frauger E, Habes D, Bernard O, Debray D,. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. Transplantation 2003: 15: 152-155.
70. Zvidi I, Gal E, Rachamimov R, Niv Y,. Tacrolimus-induced intestinal angioedema: Diagnosis by capsule endoscopy. Case Rep Gastroenterol 2007: 1: 1-6.
71. Antunes J, Gouveia C, Brito MJ,. Risks of cyclosporine therapy in paediatric age. Acta Med Port 2010: 23: 915-920.
72. Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH,. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004: 4: 130-131.
73. Feng LX, Ravindranath N, Dym M,. Stem cell factor/c-kit upregulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia. J Biol Chem 2000: 275: 25572-25576.
74. Robson M, Côte I, Abbs I, Koffman G, Goldsmith D,. Thrombotic microangiopathy with sirolimus-based immunosuppression: Potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant 2003: 3: 324-327.
75. Franco A, Hernandez D, Capdevilla L, et al., De novo hemolytic uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: Role of sirolimus. Transplant Proc 2003: 35: 1764-1766.
76. Courtellemont C, Guitard J, Mehrenberger M, et al., Thrombotic microangiopathy in a sirolimus-treated renal transplant patient receiving gemcitabine for lung cancer. Clin Nephrol 2007: 67: 114-118.
77. Barone GW, Gurley BJ, Abul-Ezz SR, Gökden N,. Sirolimus-induced thrombotic microangiopathy in a renal transplant patient. Am J Kidney Dis 2003: 42: 202-206.
78. Avitzur Y, Jimenez-Rivera C, Fecteau A, Jones N, Ngan BY, Ng VL,. Interstitial granulomatous pneumonitis associated with sirolimus in a child after liver transplantation. J Pediatr Gastroenterol Nutr 2003: 37: 91-94.
79. Morath C, Schwenger V, Ksoll-Rudek D, et al., Four cases of sirolimus-associated interstitial pneumonitis: Identification of risk factors. Transplant Proc 2007: 39: 99-102.
80. Champion L, Stern M, Israël-Biet D, et al., Brief communication: Sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med 2006: 144: 505-509.
81. Morelon E, Stern M, Israël-Biet D, et al., Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001: 72: 787-790.
82. Gupte GL, Mahadevan S, Clarke JR, Alton H, Beath SV,. Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms. World J Gastroenterol 2007: 13: 5151-5153.
83. Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI,. Sirolimus immunosuppression in pediatric heart transplant recipients: A single-center experience. J Heart Lung Transplant 2005: 24: 184-189.
84. Sayin B, Karakayali H, Colak T, et al., Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion. Transplant Proc 2009: 41: 2789-2793.
85. Pisani F, Buonomo O, Iaria G, et al., Sirolimus in kidney transplantation from marginal donors. Transplant Proc 2004: 36: 495-496.
86. Merkel S, Mogilevskaja N, Mengel M, Haller H, Schwarz A,. Side effects of sirolimus. Transplant Proc 2006: 38: 714-715.
87. Alvarez-Garcia O, Carbajo-Pérez E, Garcia E, et al., Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol 2007: 22: 954-961.
88. Alvarez-García O, García-Lõpez E, Loredo V, et al., Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int 2010: 78: 561-568.
89. Romero DF, Buchinsky FJ, Rucinsky B, et al., Rapamycin: A bone sparing immunosuppressant? J Bone Miner Res 1995: 10: 760-768.
90. Jimenez-Rivera C, Avitzur Y, Fecteau AH, Jones N, Grant D, Ng VL,. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatr Transplant 2004: 8: 243-248.
91. Meyers KEC, Kasap B, Palmer JA, Baluarte JH,. Conversion to sirolimus in renal transplant (tx) recipients: Single center experience (abstract). Pediatr Transplant 2009: 13 (Suppl. 1): 131.
92. González D, García CD, Azõcar M, et al., Growth of kidney-transplanted pediatric patients treated with sirolimus. Pediatr Nephrol 2011: 26: 961-966.
93. Rangel GA, Ariceta G,. Growth failure associated with sirolimus: Case report. Pediatr Nephrol 2009: 24: 2047-2050.
94. Dharnidharka VR, Ho PL, Stablein DM, Harmon WE, Tejani AH,. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: A report of the North American pediatric renal transplant cooperative study. Pediatr Transplant 2002: 6: 396-399.
95. Cullis B, D'souza R, McCullagh P, et al., Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006: 47: e67-e72.
96. Pascual J,. Post-transplant lymphoproliferative disorder-the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007: 22 (Suppl. 1): i27-i35.
97. Nepomuceno R, Balatoni C, Natkunam Y, Snow AL, Krams SM, Martinez OM,. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Ebstein-Barr virus B-cell lymphomas. Cancer Res 2003: 63: 4472-480.
98. Muthukkumar S, Ramesh T, Bondada S,. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 1995: 60: 264-270.
99. Mathew T, Kreis H, Friend P,. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients; results from five multicenter studies. Clin Transplant 2004: 18: 446-449.
100. Zaltzman J, Prassad R, Chun K, Jothy S,. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant 2005: 20: 1748-1751.
101. Kirk AD, Cherikh WS, Ring M, et al., Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007: 7: 2619-2625.
102. Burroughs TE, Swindle JP, Salvalaggio PR, et al., Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. Transplantation 2009: 88: 367-373.
103. Al-Uzri A, Stablein DM, R AC,. Posttransplant diabetes mellitus in pediatric renal transplant recipients: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001: 72: 1020-1024.
104. Furth S, Neu A, Colombani P, Plotnick L, Turner ME, Fivush B,. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol 1996: 10: 64-66.
105. McKee M, Segev D, Wise B, et al., Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients. J Pediatr Surg 1997: 32: 688-690.
106. Moxey-Mims MM, Kay C, Light JA, Kher KK,. Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506). Transplantation 1998: 65: 617-619.
107. Shapiro R,. Tacrolimus in pediatric renal transplantation: A review. Pediatr Transplant 1998: 2: 270-276.
108. SEARCH for D iabetes in Y outh S tudy G roup. The burden of diabetes mellitus among US youth: Prevalence estimates from the SEARCH for diabetes in youth study. Pediatrics 2006: 118: 1510-1518.
109. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP,. Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 2001: 12: 583-588.
110. Hjelmesaeth J, Hartmann A, Kofstad J, et al., Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997: 15: 979-983.
111. Romagnoli J, Citterio F, Nanni G, et al., Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 2006: 38: 1034-1036.
112. Ciancio G, Burke GW, Gaynor JJ, et al., A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004: 77: 252-258.
113. Gnatta D, Keitel E, Heineck I, et al., Use of tacrolimus and the development of posttransplant diabetes mellitus: A Brazilian single-center, observational study. Transplant Proc 2010: 42: 475-458.
114. Arellano EM, Campistol JM, Oppenheimer F, Rovira J, Diekmann F,. Sirolimus monotherapy as maintenance immunosuppression: Single-center experience in 50 kidney transplant patients. Transplant Proc 2007: 39: 2131-2134.
115. Alexander RT, Langlois V, Tellier R, Robinson L, Hebert D,. The prevalence of BK viremia and urinary viral shedding in a pediatric renal transplant population: A single-center retrospective analysis. Pediatr Transplant 2006: 10: 586-592.
116. Puliyanda DP, Toyoda M, Traum AZ, et al., Outcome of management strategies for BK virus replication in pediatric renal transplant recipients. Pediatr Transplant 2008: 12: 180-186.
117. Ginevri F, De Santis R, Comoli P, et al., Polyomavirus BK infection in pediatric kidney-allograft recipients: A single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003: 75: 1266-1270.
118. Lipshutz GS, Flechner SM, Govani MV, Vincenti F,. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004: 4: 2132-2134.
119. Smith JM, Dharnidharka VR, Talley L, Martz K, Mcdonald RA,. BK virus nephropathy in pediatric renal transplant recipients: An analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007: 2: 1037-1042.
120. Ginevri F, Azzi A, Hirsch HH, et al., Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007: 7: 2727-2735.
121. Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD,. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: Incidence, course, and clinical outcomes. Transplantation 2007: 84: 83-88.